Moderna to apply for emergency authorisation in US and Europe after Covid vaccine shows 100 pc efficacy iagainst severe cases
Washington/IBNS: Drug manufacturer Moderna has said after full results of a late stage study showed its Covid-19 vaccine has 94.1% effectiveness and no serious safety concerns, it has decided to apply for US and European emergency authorization on Monday, said a Reuters report.
The company also reported that the vaccine showed consistent efficacy across gender, race, ethnicity and age demographics and proved 100 per cent efficient in protecting against severe cases of the disease that has so far claimed 1.5 million people across the globe, said the report.
Earlier, Pfizer and BioNTech, which had a 95% efficacy rate in trials, received emergency use authorization in the US this year.
According to the report, out of the 196 volunteers who contracted COVID-19 in the trial with more than 30,000 people, 185 were administered a placebo while 11 were given the vaccine.
Moderna said it had 30 severe cases, all of whom were in the placebo group, indicating 100% effectiveness of the vaccine in preventing severe cases.